2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
BPC-157, also called Bpc-157, is a synthetic pentadecapeptide derived from gastric proteins. It has shown notable reparative and anti-inflammatory properties across diverse preclinical models. A separate study describes it as a gastric pentadecapeptide and investigated its inhibitory potential alongside two newly designed hybrid analogs, CIARA-1 and CIARA-2.
One review names TB-500 as a thymosin beta-4 fragment and lists it among unapproved peptides marketed direct to patients. A separate scoping review states that thymosin beta-4, also called TB-500, is one of six emerging peptides it summarizes for musculoskeletal recovery and enhancement in animal and human models.
GHK-Cu is Glycyl-L-histidyl-L-lysine copper(II), a copper complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK). It is described as the copper-bound form of the human tripeptide glycyl-L-histidyl-L-lysine, with preclinical evidence for tissue regeneration, anti-inflammatory action and antioxidant capacity. A review notes that GHK and GHK-Cu have been studied for matrix remodeling, inflammation, redox regulation, angiogenesis and tissue repair, and that formulation affects coordination state, stability, pharmacokinetics and toxicity. In one in vitro study, GHK-Cu was formulated with Torilis japonica extract (TJE) and examined for anti-atopic and skin-regenerative properties in TNF-α/IFN-γ-stimulated HaCaT cells.
In animal studies, BPC 157 was reported to support new blood vessel formation (angiogenesis), collagen production (collagen synthesis), fibroblast activity, and modulation of nitric oxide pathways. These effects were described as contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue in those animal studies. In a laboratory study using human arterial tissue, BPC 157 induced concentration-dependent vasorelaxation, predominantly mediated via an endothelium-dependent nitric oxide pathway.
According to the review, thymosin beta 4 (TB4) has not received full US Food and Drug Administration approval. The review reports that studies show TB4 significantly promotes corneal wound healing after injury, and that this led to a clinical trial of RGN-259, with full FDA approval still pending. The review also states that most of these regenerative peptides, which include TB-4, remain unapproved by the FDA, and that clinical evidence in humans is limited.
In preclinical animal studies, GHK-Cu reduced inflammation by suppressing the signaling molecules TGF-β and IL-6. A review describes GHK-Cu as an endogenous matricryptin released from collagen Iα2 and SPARC. The review links it to tissue matrix organization, fibrosis reduction and antioxidant defense.
In preclinical animal studies, BPC 157 was reported to support angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways. These effects were described as contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue in those studies. In animal studies, BPC 157 was proposed to protect skeletal muscle against ischemia-reperfusion injury by attenuating oxidative stress, modulating apoptosis, reducing inflammation, and supporting angiogenic activity.
In a randomized, placebo-controlled, double-blind trial of 96 STEMI patients, the overall difference in infarcted area between the rhTB4 group and the placebo group was not significant. In a subgroup of that trial, infarcted areas were significantly reduced at 90-day follow-up in patients whose first rhTB4 dose was given within 8 h after PCI (n = 43) compared with placebo.
Copper tripeptide-1 is another name for GHK-Cu, which is the copper-bound form of the human tripeptide glycyl-L-histidyl-L-lysine. One source describes GHK-Cu as a human tripeptide derivative, listed as copper tripeptide-1.
A review states that independent blinded replication, dose-response and therapeutic-window studies, pharmacokinetic/pharmacodynamic characterization, rigorous toxicology, and ultimately controlled human studies would be required before clinical translation of BPC 157 could be considered. The same review describes BPC-157 as an unapproved peptide sold on the unregulated (illicit) market, and states that it lacks an established human safety profile.
In structural modeling, the tandem form (tTB4) was found to be able to simultaneously bind and sequester two G-actin molecules, which gave it a mechanistic advantage over standard TB4 in enhancing actin polymerization. In a murine alkali-induced corneal injury model, tTB4 promoted corneal wound healing and reduced scarring with greater efficacy than TB4. Because tTB4 can be produced by bacterial fermentation, its synthesis is described as simplified and more cost-effective than that of TB4.
Across a group of reviewed peptides that includes GHK-Cu, 67% of identified publications used preclinical animal models, and the review did not report this figure for GHK-Cu separately. For these reviewed peptides, including GHK-Cu, human clinical studies were limited to a handful of investigations. Most of those human investigations lacked robust controls or rigorous study designs, according to the review.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.